Document is current

Article History

Received: 30 January 2024

Revised: 3 June 2024

Accepted: 18 June 2024

First Online: 6 July 2024

Competing interests

: RK: clinical trial funding (to her institution) from Clovis Oncology; clinical trial grants from Merck Sharp & Dohme; consultancy for Pharmaceutica and Shattuck Pharma; honoraria from Clovis Oncology, AstraZeneca, GlaxoSmithKline, and Incyte; travel support from AstraZeneca, GlaxoSmithKline, and Sierra Oncology; and participation on data safety monitoring boards or advisory boards for Clovis Oncology, AstraZeneca, BeiGene, Eisai, GlaxoSmithKline, Incyte, iTeos Therapeutics, PharmaMar and Roche. AL: fees (to her institution) for advisory boards and educational presentations from AstraZeneca, Clovis, MSD, and GSK and a grant for translational research from AstraZeneca; she is the principal investigator on trials funded by AstraZeneca, MSD, and GSK. AO: consulting/advisory roles for Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro, ImmunoGen, Genmab, Mersana, GSK, Deciphera, AGENUS, Corcept Therapeutics, Eisai, EMD Serono, Medison, Merck Sharp & Dohme, Novocure, prIME Oncology, Shattuck Labs, Sutro Biopharma, ITeos Therapeutics, and Amgen; research funding (to her institution) from AbbVie, Abililty Pharmaceuticals, Advaxis, Aeterna Zentaris, Aprea Therapeutics, Clovis Oncology, Eisai, Roche, Regeneron, Agenus, AstraZeneca, BeiGene, Belgian Gynaecological Oncology Group (BGOG), BMS, Corcept Therapeutics, ImmunoGen, Iovance Biotherapeutics, Lilly, MedImmune, Merck, Merck Sharp & Dohme, Mundipharma Research, Novartis FarmacÃutica, Seagen, Seattle Genetics, Sutro Biopharma, Tesaro, and Verastem; and travel/accommodation/expenses from AstraZeneca, Clovis Oncology, PharmaMar, and Roche. AR: institutional grants from Eisai, PharmaMar, and Roche; honoraria from AstraZeneca, MSD, Clovis, GSK, PharmaMar, and Eisai; advisory board roles at AstraZeneca, MSD, Clovis, GSK, PharmaMar, and Eisai; and travel support from AstraZeneca, GSK, and PharmaMar. AG: honoraria from AstraZeneca, MSD, GSK, Clovis, and Roche. SC, CSS, LMo: Genentech employees and Roche shareholders. AS, ML-H: Roche employees and shareholders. JW: employee of Roche Products, Ltd, and a Roche shareholder. JX, KKL: former employees of Clovis Oncology. YG: former employee of Genentech. IR-C: honoraria from Abbvie, Advaxis, Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Deciphera, Genmab, GlaxoSmithKline, MERSANA, MSD Oncology, OxOnc, Pfizer, PharmaMar, Roche, and Tesaro; consulting/advisory roles for Abbvie, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Deciphera, Genmab, GlaxoSmithKline, Mersana, MSD Oncology, Pfizer, PharmaMar, Roche, and Tesaro; research funding from BMS and MSD Oncology; and travel/accommodation/expenses from Advaxis, AstraZeneca, BMS, Clovis Oncology, GlaxoSmithKline, PharmaMar, Roche, and Tesaro. LMi declares no competing interests.

: The study was approved by the Institutional Review Board or Ethics Committee at each site before study initiation. All patients provided written informed consent before undergoing any study-specific procedures. The study was conducted in full conformance with the International Conference on Harmonisation E6 guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of each country if they afforded greater protection to the individual.

: Not applicable.